Introduction {#Sec1}
============

Daptomycin, a cyclic polypeptide and a semisynthetic lipopeptide antibiotic, is derived from *Streptomyces roseosporus*^[@CR1]^. The native molecule is anionic, although binding to the bacterial membrane and exploitation of the bactericidal activity that is typical of daptomycin require calcium. Daptomycin exhibits bactericidal activity by penetrating the bacterial cell wall and binding to the cytoplasmic membrane, thereby causing rapid depolarization of the membrane. This results in the loss of membrane potential and bacterial cell death^[@CR2]^. Because of the unique mechanism of action, daptomycin-resistance has rarely been documented. However, treatment failure due to daptomycin resistance was observed in a patient with high-grade methicillin-sensitive *Staphylococcus aureus* (MRSA) bacteraemia^[@CR3],[@CR4]^.

*Staphylococcus epidermidis* infections, particularly catheter-related bloodstream and surgical site infections and infective endocarditis, are common in hospitals^[@CR5],[@CR6]^. *S. epidermidis* mostly engages beneficially in the host defence and immune maturation system but may show infective behaviour under certain circumstances^[@CR7]^. Although a reduction in the susceptibility of *S. aureus* to daptomycin is well established, that of *S. epidermidis* is unknown. A high minimum inhibitory concentration (MIC) of daptomycin may contribute to treatment failure in patients with *S. epidermidis*, especially methicillin-resistant *S. epidermidis* (MRSE), infections. We, therefore, conducted a retrospective cohort study to determine the predictive value of daptomycin susceptibility.

Results {#Sec2}
=======

The data from 1,337 patients were included in this study, of whom, 1,299 (97.2%) had a lower daptomycin MIC (≤1 mg/L) for *S. epidermidis* and 38 (2.8%) had a higher daptomycin MIC (MIC \>1 mg/L) for *S. epidermidis*. These patients were categorized into low (≤1 mg/L; sensitive) and high (\>1 mg/L; resistant) MIC groups. A comparison of the demographic characteristics between the two groups is shown in Table [1](#Tab1){ref-type="table"}. The groups were equivalent with respect to age, sex, implantation, vancomycin susceptibility, and prior use of linezolid, cephem, aminoglycoside, fluoroquinolone, and sulfamethoxazole/trimethoprim. However, there were significant differences in terms of prior use of glycopeptide (*P* = 0.003), daptomycin (*P* = 0.018), penicillin (*P* = 0.016), carbapenem (*P* = 0.014), and tetracycline (*P* = 0.016), as well as teicoplanin susceptibility (*P* \< 0.0001).Table 1Patient demographics.CharacteristicsDaptomycin susceptibility*P*-valueSensitive (%)Resistant (%)Total1299 (97.2)38 (2.8)**Age**\<65632 (48.7)18 (47.4)0.876≥65667 (51.4)20 (52.6)**Sex (male/female)**Male772 (59.4)24 (63.2)0.645Female527 (40.6)14 (36.8)**Implantation, catheter**With223 (17.2)11 (28.9)0.060Without1076 (82.8)27 (71.1)**Previous glycopeptide use**Yes305 (23.5)17 (44.7)0.003No994 (76.5)21 (55.3)**Vancomycin susceptibility**MIC \< 2 mg/L1016 (78.2)27 (71.1)0.293MIC ≥ 2 mg/L283 (21.8)11 (28.9)**Teicoplanin susceptibility**MIC \< 16 mg/L1212 (93.3)23 (60.5)\<0.0001\*MIC ≥ 16 mg/L87 (6.7)15 (39.5)**Previous linezolid use**Yes29 (2.2)2 (5.3)0.219No1270 (97.8)36 (94.7)**Previous daptomycin use**Yes91 (7.0)7 (18.4)0.018\*No1208 (93.0)31 (81.6)**Previous penicillin use**Yes469 (36.1)21 (55.3)0.016No830 (63.9)17 (44.7)**Previous cephem use**Yes863 (66.4)28 (73.7)0.350No436 (33.6)10 (26.3)Previous carbapenem useYes497 (38.3)22 (57.9)0.014No802 (61.7)16 (42.1)**Previous aminoglycoside use**Yes97 (7.5)3 (7.9)0.921No1202 (92.5)35 (92.1)**Previous tetracycline use**Yes68 (5.2)6 (15.8)0.016\*No1231 (94.8)32 (84.2)**Previous fluoroquinolone use**Yes659 (50.7)24 (36.8)0.131No640 (49.3)14 (63.2)**Previous sulfamethoxazole/trimethoprim use**Yes237 (18.2)7 (18.4)0.978No1062 (81.8)31 (81.6)\*The Fisher's exact test.

The relationships between the study variables and daptomycin resistance are shown in Table [2](#Tab2){ref-type="table"}. In the crude logistic regression analysis, a higher teicoplanin MIC value (*P* \< 0.0001) and prior use of glycopeptide (*P* = 0.005), daptomycin (*P* = 0.023), penicillin (*P* = 0.018), carbapenem (*P* = 0.016), and tetracycline (*P* = 0.020) were associated with increased risk of developing daptomycin resistance. In the multiple analysis, only higher teicoplanin MIC value was independently associated with an increased risk of daptomycin resistance (adjusted OR = 8.01, 95% CI = 3.86--16.18, *P* \< 0.0001). Additionally, the MIC of daptomycin was significantly positively correlated with that of teicoplanin (Pearson correlation coefficient (r) = 0.55, *P* \< 0.0001).Table 2Relationships between the studied variables and daptomycin resistance.VariablesCrude OR (95% CI)*P*-valueAdjusted OR (95% CI)\**P*-valueAge (≥65)1.05 (0.55--2.03)0.8761.25 (0.67--2.46)0.518Sex (male/female)1.17 (0.61--2.34)0.6431.07 (0.55--2.18)0.844Implantation, catheter1.97 (0.92--3.92)0.078Previous glycopeptide use2.64 (1.36--5.06)0.0051.91 (0.95--3.77)0.070Higher vancomycin MIC value (MIC ≥2 mg/dL)1.46 (0.69--2.91)0.309Higher teicoplanin MIC value (MIC ≥16 mg/dL)9.09 (4.49--17.90)\<0.00018.01 (3.86--16.18)\<0.0001Previous linezolid use2.43 (0.38--8.52)0.290Previous daptomycin use3.00 (1.19--6.62)0.023Previous penicillin use2.19 (1.14--4.24)0.018Previous cephem use1.41 (0.70--3.09)0.341Previous carbapenem use2.22 (1.16--4.34)0.016Previous aminoglycoside use1.06 (0.25--3.02)0.922Previous tetracycline use3.40 (1.25--7.86)0.020Previous fluoroquinolone use1.67 (0.87--3.33)0.128Previous sulfamethoxazole/trimethoprim use1.01 (0.41--2.20)0.978\*Simultaneous adjustment of each variable that was significant (*P* \< 0.01) in the crude model.

Discussion {#Sec3}
==========

Our findings demonstrate that a lower susceptibility to teicoplanin was independently associated with an increased risk of lower susceptibility to daptomycin in patients with *S. epidermidis* infection. Teicoplanin, a glycopeptide, currently used for the treatment of potentially serious infections caused by β-lactam-resistant gram-positive pathogens, is not approved in the United States. However, in Europe, Japan, and Taiwan, it is commonly prescribed as vancomycin. Teicoplanin is considered as effective as vancomycin for the treatment of MRSA bacteraemia^[@CR8]^. In cases of MRSE infection, glycopeptides or daptomycin is used for the treatment of MRSA.

Daptomycin resistance has been reported in cases of bacteraemia, endocarditis, osteomyelitis, skin and soft-tissue infections, and prosthetic joint infection. Where daptomycin non-susceptibility developed, other antibiotics were used previously (mainly vancomycin or teicoplanin)^[@CR4]^. Thus, a vast majority of cases of daptomycin resistance were reported in patients previously treated with a glycopeptide antibiotic. The heterogeneous vancomycin-intermediate *S. aureus* (hVISA) with a vancomycin MIC of 1--2 mg/L were resistant to daptomycin. However, a higher MIC (≥2 mg/L) of vancomycin or other antimicrobials did not affect daptomycin resistance in this study. The majority of previous reports did not describe the mechanism of daptomycin resistance. A previous study on vancomycin resistance in VISA strains, however, indicated that a thickened cell wall was a common characteristic among the VISA strains, serving as a physical barrier against the penetration of vancomycin molecules and resulting in vancomycin resistance^[@CR9],[@CR10]^. Furthermore, Garcia *et al*. reported that MRSE was the leading cause of coagulase-negative staphylococcal infective endocarditis, and patients receiving vancomycin had higher mortality rates than those receiving cloxacillin. The mortality was higher among patients having isolates with a vancomycin MIC of ≥2 mg/L^[@CR11]^. Several mechanisms contributing to the reduced susceptibility of Staphylococci to daptomycin have been reported, many of which describe a common resistance mechanism of *S. aureus* and *S. epidermidis* to antibiotics^[@CR4],[@CR12]^. The mechanism of *S. epidermidis* resistance is similar to that of VISA and hVISA strains^[@CR13],[@CR14]^. A possible explanation of this correlation is that the thickened cell wall acts as a common barrier to daptomycin and teicoplanin penetration, although daptomycin does not bind to peptidoglycan to form a subsequent physical barrier within the cell wall^[@CR15],[@CR16]^. As daptomycin (molecular weight 1620.67 Da) and teicoplanin (molecular weight 1564.25--1893.68 Da) are relatively larger in molecular size as compared to vancomycin (molecular weight 1485.7 Da), we suggest that daptomycin might not be able to efficiently penetrate the cell wall if it is as thick as that of *S. epidermidis*. In this case, daptomycin might be impeded by the thickened cell wall before reaching the cytoplasmic membrane resulting in ineffective bactericidal function in the target cells.

Furthermore, the ability of *S. epidermidis* to produce biofilms ensures significant resistance to antibiotics and impairs the host innate immune response^[@CR6]^. In these situations, the use of an antimicrobial agent capable of crossing the biofilm enhances the treatment efficacy. In this context, the ability of daptomycin to penetrate rapidly into the biofilm produced by *S. epidermidis* is well known^[@CR17]^. However, daptomycin treatment is not suitable for daptomycin-resistant *S. epidermidis* infection. In this study, patients with bloodstream infections caused by daptomycin resistant *S. epidermidis* were mainly treated with vancomycin. Hence, there was no difference in the treatment duration between the sensitive (12.2 days) and resistant (13.0 days) groups. There are some limitations to our study, including the retrospective design. Furthermore, genetic analysis of *S. epidermidis* was not performed. Due to the very small number of patients in the resistance group (n = 38), our confidence interval was wide which provides a lesser statistical certainty, and hence, the positive significant results might have happened by chance.

In conclusion, a higher teicoplanin MIC may predict the resistance of *S. epidermidis* to daptomycin. A more effective therapeutic strategy against daptomycin-resistant *S. epidermidis* bacteraemia, such as initial regimens that combine different classes of antimicrobial agents or early transition to an alternative treatment, is required. The true significance of the clinical activity of daptomycin against teicoplanin-resistant *S. epidermidis* warrants further explanation and investigation in future clinical studies.

Patients and Methods {#Sec4}
====================

Ethical approval of the study protocol {#Sec5}
--------------------------------------

The study was carried out in accordance with the guidelines on human studies adopted by the ethics committee of Ehime University Hospital (Ehime, Japan; review board approval no. 1602008), the Declaration of Helsinki, and the Ethical Guidelines on Medical and Health Research Involving Human Subjects by the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labour and Welfare of Japan. The Japanese law does not mandate obtaining individual informed consent from participants in non-invasive observational trials, such as the present study. Therefore, we used our official pharmacy website as an opt-out method rather than obtaining written or verbal informed consent from each patient.

Patients and study design {#Sec6}
-------------------------

The data were collected from 1 January 2013 to 31 December 2016 at Ehime University Hospital. In this study, a total of 1699 patients with *S. epidermidis* infection were included and 362 patients were excluded due to missing data on daptomycin MIC values. The data of 1337 patients with *S. epidermidis* infection available for analysis in a retrospective study (participation rate, 78.7%). As compared to the excluded patients, the study patients were more likely to use glycopeptide, daptomycin, and cephem, and less likely to show a higher teicoplanin susceptibility (MIC ≥16 mg/L) or use fluoroquinolone and sulfamethoxazole/trimethoprim. The following clinicopathological factors were obtained from the medical charts: age, sex, implantation, resistance to vancomycin or teicoplanin, and history of antimicrobial therapy. Where one or more samples were determined as resistant, the patients were included in the resistant group. The criteria for MIC value were according to the CLSI M100 S28 guidelines. According to the CLSI guidelines, an MIC of ≤4 mg/L signifies sensitivity to vancomycin. However, a low success rate of vancomycin therapy with a vancomycin MIC of ≥2 mg/L has previously been reported^[@CR18],[@CR19]^. Therefore, patients with a vancomycin MIC of ≥2 mg/L were included in the lower susceptibility group. The determination of MIC was carried out using the standard broth microdilution method.

Statistical analysis {#Sec7}
--------------------

χ^2^-test and Fisher's exact test were used to compare the categorical variables. Using logistic regression analysis, we calculated the crude and adjusted odds ratios (ORs) with their 95% confidence intervals (CIs). Parameters with a *P*-value of \< 0.01 in the crude analyses were considered for inclusion in the multivariate model. All statistical analyses were performed using the SAS software package version 9.4 (SAS Institute, Inc., NC, USA).
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